Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 9/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580766 | 0.81 | FYN (0.40) | FYNBRD4ADORA2AADORA1GRIN1 | |
| SCHEMBL21729201 | 0.80 | PLA2G2A (0.51) | PLA2G2A | |
| SCHEMBL9911076 | 0.76 | PLA2G2A (0.48) | PLA2G2A | |
| SCHEMBL14512236 | 0.74 | PLAT (0.37) | PLA2G2AGRIN1GRIN2B | |
| SCHEMBL5580719 | 0.73 | FYN (0.40) | FYNADORA2AADORA1PDE10ADRD2 | |
| SCHEMBL21729183 | 0.72 | DAO (0.46) | PLA2G2ABRD4 | |
| SCHEMBL9911070 | 0.71 | HTT (0.60) | PLA2G2AALDH1A1 | |
| SCHEMBL11838787 | 0.70 | PLA2G2A (0.54) | PLA2G2A | |
| SCHEMBL21729202 | 0.70 | PLA2G2A (0.65) | PLA2G2A | |
| SCHEMBL5580811 | 0.70 | CFD (0.53) | FYNGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105959-A1 | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1604971-A1 | CINNAMYL ALCOHOL DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105959-A1 | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient | LPL, GPR119, EBP | PLA2G2A 4117/4885FYN 1650/4885BRD4 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.